Leki immunomodulujące oraz inhibitory proteasomów w leczeniu chorych na szpiczaka plazmocytowego z niewydolnością nerek

@article{Charliski2012LekiIO,
  title={Leki immunomodulujące oraz inhibitory proteasom{\'o}w w leczeniu chorych na szpiczaka plazmocytowego z niewydolnością nerek},
  author={Grzegorz Charliński and G. Ostrowski and E. Wiater},
  journal={Acta haematologica Polonica},
  year={2012},
  volume={43},
  pages={173-186}
}
  • Grzegorz Charliński, G. Ostrowski, E. Wiater
  • Published 2012
  • Medicine
  • Acta haematologica Polonica
    • STRESZCZENIE Niewydolnośc nerek (NN) stwierdzana jest u 50% chorych na szpiczaka plazmocytowego (SzP) i zazwyczaj jest wykladnikiem duzej masy guza, bardziej agresywnego przebiegu choroby, a takze pogarsza jakośc zycia, sprzyja rozwojowi powiklan i zwieksza ryzyko zgonu. chorzy na SzP z ciezką NN stanowią powazny problem terapeutyczny z powodu uzyskiwania gorszych wynikow leczenia. wprowadzenie do terapii SzP bortezomibu, talidomidu i lenalidomidu spowodowalo wydluzenie przezywalności chorych… CONTINUE READING
    View via Publisher
    2 Citations
    Background Citations
    1

    Topics from this paper

    Explore Further: Topics Discussed in This Paper

    2 Citations
    Citation Type

    Citation Type

    Strategie optymalizacji terapii lenalidomidem u chorych na szpiczaka plazmocytowego
    Frequency of the malignant neoplasms in population commencing renal replacement therapy (rrt) in the years 2001-2015 – one-unit experience
    • PDF

    References

    SHOWING 1-10 OF 75 REFERENCES
    Lenalidomide‐induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment‐naïve patients undergoing front‐line lenalidomide and dexamethasone therapy
    • 83
    Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM
    • 13
    A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
    • 259
    • PDF
    Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02
    • 20
    Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)
    • 60
    Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol
    • 5
    Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis
    • 40
    VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
    • 143
    Safety and efficacy of bortezomib‐based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA
    • 73
    Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial
    • 20